# Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma

> **NCT01737905** · PHASE3 · COMPLETED · sponsor: **Amphastar Pharmaceuticals, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Epinephrine HFA-MDI (E004)
- **DRUG:** Placebo-HFA

## Key facts

- **NCT ID:** NCT01737905
- **Lead sponsor:** Amphastar Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2013-03
- **Final completion:** 2013-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2016-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01737905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01737905, "Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01737905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*